We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Smartphone-Based Technique Helps Doctors Assess Hematological Disorders

By LabMedica International staff writers
Posted on 01 Jun 2020
Print article
Image: High-quality spectra acquired by the image-guided hyperspectral line-scanning system and the mHematology mobile application. The device assesses blood hemoglobin without drawing blood (Photo courtesy of Purdue University).
Image: High-quality spectra acquired by the image-guided hyperspectral line-scanning system and the mHematology mobile application. The device assesses blood hemoglobin without drawing blood (Photo courtesy of Purdue University).
As one of the most common clinical laboratory tests, blood hemoglobin tests are routinely ordered as an initial screening of reduced red blood cell production to examine the general health status before other specific examinations.

Blood hemoglobin tests are extensively performed for a variety of patient care needs, such as anemia detection as a cause of other underlying diseases, assessment of hematologic disorders, transfusion initiation, hemorrhage detection after traumatic injury, and acute kidney injury.

Biomedical Engineers at Purdue University (West Lafayette, IN, USA) and their colleagues have developed a way to use smartphone images of a person's eyelids to assess blood hemoglobin levels. The ability to perform one of the most common clinical laboratory tests without a blood draw could help reduce the need for in-person clinic visits, make it easier to monitor patients who are in critical condition, and improve care in low- and middle-income countries where access to testing laboratories is limited.

The scientists tested the new technique, called mHematology, with 153 volunteers who were referred for conventional blood tests at the Moi University Teaching and Referral Hospital (Eldoret, Kenya). They used data from a randomly selected group of 138 patients to train the algorithm, and then tested the mobile health app with the remaining 15 volunteers. The results showed that the mobile health test could provide measurements comparable to traditional blood tests over a wide range of blood hemoglobin values.

The team created a mobile health version of the analysis by using an approach known as spectral super-resolution spectroscopy. This technique uses software to virtually convert photos acquired with low-resolution systems such as a smartphone camera into high-resolution digital spectral signals. They selected the inner eyelid as a sensing site because microvasculature is easily visible there; it is easy to access and has relatively uniform redness. The inner eyelid is also not affected by skin color, which eliminates the need for any personal calibrations. The prediction errors for the smartphone technique were within 5% to 10% of those measured with clinical laboratory blood.

Young L. Kim, PhD, MSCI, an associate professor and senior author of the study said, “Our new mobile health approach paves the way for bedside or remote testing of blood hemoglobin levels for detecting anemia, acute kidney injury and hemorrhages, or for assessing blood disorders such as sickle cell anemia.” The study was published on May 21, 2020 issue of the journal Optica.

Related Links:
Purdue University
Moi University Teaching and Referral Hospital


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more